title: Intravitreal bevacizumab in inflammatory ocular neovascularization.
abstract: OBJECTIVE
  To assess the role of bevacizumab in inflammatory ocular neovascularization.
  
  
  METHODS
  Retrospective, multicenter, consecutive case series of inflammatory ocular neovascularization.
  
  
  METHODS
  Patients with inflammatory ocular neovascularization of varying causes for whom standard therapy failed were treated with intravitreal injection of bevacizumab. Main outcome measures included improvement of best-corrected visual acuity (BCVA) expressed in logarithm of minimum angle of resolution units, response of inflammatory ocular neovascularization by funduscopy and angiography, and decrease in central foveal thickness as measured by optical coherence tomography at the three-month follow-up.
  
  
  RESULTS
  At the three-month follow-up, 84 eyes of 79 patients had been treated with a mean of 1.3 injections (range, one to three). Thirty-four eyes showed juxtafoveal choroidal neovascularization (CNV), 34 eyes showed subfoveal CNV, eight eyes showed peripapillary CNV, and 11 eyes showed neovascularization of the disc (NVD) or neovascularization elsewhere (NVE). BCVA improved 2.4 lines from 0.68 (6/28 or 20/94) to 0.44 (6/17 or 20/55) (P < .001). BCVA improved by one to three lines in 34.5% of the eyes, by four to six lines in 16.7% of the eyes, and by more than six lines in 14.2% of the eyes. Function was unchanged in 23.8% of the eyes. BCVA worsened in 10.7% (zero to three lines in 7.1%, more than four lines in 3.6%). Central foveal thickness decreased from baseline 346 to 252 microm (P < .001). For CNV, 32 eyes (43.2%) had complete regression after the injection, 27 (36.5%) had partial regression, five (6.8%) had no response, and 10 eyes (13.5%) were not evaluated by the contributors. For NVD or NVE, seven eyes (63.6%) had complete regression of new vessels and four eyes (36.4%) had partial regression after the injection.
  
  
  CONCLUSIONS
  Intravitreal bevacizumab led to short-term significant visual improvement and regression of inflammatory ocular neovascularization in a wide variety of inflammatory ocular diseases.
authors.affiliation: Department of Ophthalmology, American University of Beirut and Rafic Hariri University Hospital, Beirut, Lebanon. dr.ahmad@cyberia.net.lb
authors.forename: Ahmad M
authors.initials: AM
authors.lastname: Mansour
authors.forename: Friederike
authors.initials: F
authors.lastname: Mackensen
authors.forename: J Fernando
authors.initials: JF
authors.lastname: Arevalo
authors.forename: Focke
authors.initials: F
authors.lastname: Ziemssen
authors.forename: Padmamalini
authors.initials: P
authors.lastname: Mahendradas
authors.forename: Abla
authors.initials: A
authors.lastname: Mehio-Sibai
authors.forename: Nicholas
authors.initials: N
authors.lastname: Hrisomalos
authors.forename: Timothy Y Y
authors.initials: TY
authors.lastname: Lai
authors.forename: David
authors.initials: D
authors.lastname: Dodwell
authors.forename: Wai-Man
authors.initials: WM
authors.lastname: Chan
authors.forename: Thomas
authors.initials: T
authors.lastname: Ness
authors.forename: Alay S
authors.initials: AS
authors.lastname: Banker
authors.forename: Sivakami A
authors.initials: SA
authors.lastname: Pai
authors.forename: Maria H
authors.initials: MH
authors.lastname: Berrocal
authors.forename: Rania
authors.initials: R
authors.lastname: Tohme
authors.forename: Arnd
authors.initials: A
authors.lastname: Heiligenhaus
authors.forename: Ziad F
authors.initials: ZF
authors.lastname: Bashshur
authors.forename: Moncef
authors.initials: M
authors.lastname: Khairallah
authors.forename: Khalil M
authors.initials: KM
authors.lastname: Salem
authors.forename: Frank N
authors.initials: FN
authors.lastname: Hrisomalos
authors.forename: Matthew H
authors.initials: MH
authors.lastname: Wood
authors.forename: Wilson
authors.initials: W
authors.lastname: Heriot
authors.forename: Alfredo
authors.initials: A
authors.lastname: Adan
authors.forename: Atul
authors.initials: A
authors.lastname: Kumar
authors.forename: Lyndell
authors.initials: L
authors.lastname: Lim
authors.forename: Anthony
authors.initials: A
authors.lastname: Hall
authors.forename: Matthias
authors.initials: M
authors.lastname: Becker
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D002648:Child; D020256:Choroidal Neovascularization / Q000188:drug therapy* / Q000209:etiology / Q000503:physiopathology; D005128:Eye Diseases / Q000150:complications; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007267:Injections; D008297:Male; D008875:Middle Aged; D009898:Optic Disk / Q000098:blood supply; D015861:Retinal Neovascularization / Q000188:drug therapy* / Q000209:etiology / Q000503:physiopathology; D012189:Retrospective Studies; D041623:Tomography, Optical Coherence; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors; D014792:Visual Acuity / Q000502:physiology; D014822:Vitreous Body
chemical_list: D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D042461:Vascular Endothelial Growth Factor A; D000068258:Bevacizumab